Filgotinib, a Jak1 inhibitor [10], and upadacitinib, a Jak1 inhibitor with partial selectivity for Jak2, have also been approved for the treatment of psoriatic arthritis [20]. This evidence concerns the gene JAK1 and psoriatic arthritis.